Bortezomib for previously untreated multiple myeloma

Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma

(2011) Michel Delforge et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

(2011) Philippe Moreau et al.   LANCET ONCOLOGY

Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid

(2010) E. Terpos et al.   ANNALS OF ONCOLOGY

Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma

(2010) A. Waage et al.   BLOOD

Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

(2010) J.-L. Harousseau et al.   BLOOD

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

(2010) P. G. Richardson et al.   BLOOD

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients

(2010) S. Bringhen et al.   BLOOD

Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma

(2010) Donna E. Reece et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: A prospective, multicenter, open-label, randomized, two-way crossover drug—drug interaction study

(2010) Karthik Venkatakrishnan et al.   CLINICAL THERAPEUTICS

Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group

(2010) Meral Beksac et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study

(2010) Meletios A. Dimopoulos et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study

(2010) Pierre Wijermans et al.   JOURNAL OF CLINICAL ONCOLOGY

Light Chain–Induced Acute Renal Failure Can Be Reversed by Bortezomib-Doxorubicin-Dexamethasone in Multiple Myeloma: Results of a Phase II Study

(2010) Heinz Ludwig et al.   JOURNAL OF CLINICAL ONCOLOGY

Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents

(2010) Asher A. Chanan-Khan et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial

(2010) Maria-Victoria Mateos et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial

(2010) Jean-Luc Harousseau et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)

(2010) Hervé Avet-Loiseau et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial

(2010) Antonio Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group

(2010) Meletios A. Dimopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients

(2010) Antonio Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma

(2010) Marco Ladetto et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

(2010) Michele Cavo et al.   LANCET

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

(2010) María-Victoria Mateos et al.   LANCET ONCOLOGY

Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues

(2010) Michel Delforge et al.   LANCET ONCOLOGY

Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005–01 trial

(2010) P Moreau et al.   LEUKEMIA

DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma

(2009) Martin Kropff et al.   ANNALS OF HEMATOLOGY

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

(2009) S. Kumar et al.   BLOOD

Bortezomib and EGCG: no green tea for you?

(2009) J. J. Shah et al.   BLOOD

Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM)

(2009) M. Roussel et al.   BLOOD

Bortezomib induces canonical nuclear factor- B activation in multiple myeloma cells

(2009) T. Hideshima et al.   BLOOD

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

(2009) Paul G. Richardson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma

(2009) William I. Bensinger et al.   BRITISH JOURNAL OF HAEMATOLOGY

Effect of the Cytochrome P450 2C19 Inhibitor Omeprazole on the Pharmacokinetics and Safety Profile of Bortezomib in Patients with Advanced Solid Tumours, Non-Hodgkinʼs Lymphoma or Multiple Myeloma

(2009) David I. Quinn et al.   CLINICAL PHARMACOKINETICS

Home administration of bortezomib: Making a difference to myeloma patients' lives

(2009) Teresa Meenaghan et al.   European Journal of Oncology Nursing

Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 Trials

(2009) Jean-Luc Harousseau et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial

(2009) Cyrille Hulin et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma

(2009) Paul G. Richardson et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Combination Therapy With Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Myeloma

(2009) Andrzej J. Jakubowiak et al.   JOURNAL OF CLINICAL ONCOLOGY

Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy

(2009) Paul G. Richardson et al.   JOURNAL OF CLINICAL ONCOLOGY

Ascorbic acid inhibits antitumor activity of bortezomib in vivo

(2009) G Perrone et al.   LEUKEMIA

Proteasome inhibitors in the treatment of multiple myeloma

(2009) J J Shah et al.   LEUKEMIA

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial

(2009) C B Reeder et al.   LEUKEMIA

Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial

(2009) Asher Chanan-Khan et al.   LEUKEMIA & LYMPHOMA

Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma

(2009) F. van Rhee et al.   MOLECULAR CANCER THERAPEUTICS

Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma

(2009) Jean-Luc Harousseau et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multiple myeloma

(2008) R. A. Kyle et al.   BLOOD

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial

(2008) A. Palumbo et al.   BLOOD

Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up

(2008) Rakesh Popat et al.   BRITISH JOURNAL OF HAEMATOLOGY

Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2

(2008) Mauricio Pineda-Roman et al.   BRITISH JOURNAL OF HAEMATOLOGY

Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma

(2008) P. Moreau et al.   HAEMATOLOGICA

Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma

(2008) S. Vincent Rajkumar et al.   JOURNAL OF CLINICAL ONCOLOGY

Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study

(2008) Asher Chanan-Khan et al.   JOURNAL OF CLINICAL ONCOLOGY

Bone marrow microenvironment and the identification of new targets for myeloma therapy

(2008) K Podar et al.   LEUKEMIA

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE